1.®(tremelimumab-actl) [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023.2.IMFINZI®(durvalumab) [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023.3.US Department of Health and Human Services. Centers for Medicare & Medicaid Services (CMS...
Imjudo (tremelimumab-actl) is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). What Are Side Effects of Imjudo? Imjudo may cause serious side eff...
What is the most important information I should know about IMFINZI®(durvalumab) and IMJUDO®(tremelimumab-actl)? IMFINZI is a medicine that may treat certain cancers by work... IMFINZI and IMJUDO are medicines that may treat certain cancers by working with your immune system. IMFINZI and ...